TransCode Therapeutics Inc (RNAZ) Share Price

Live the dream with president Trump

HAIL BREAKTHROUGH USA USA USA USA
https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/russia-claims-groundbreaking-development-of-mrna-based-cancer-vaccine-all-we-know-about-it-so-far/amp_articleshow/116989292.cms

We must rise and shock the world once and for all

We have been deep down in the dark for many years, investors lost everything 99.999% since IPO @ $150,000 a share

Is this clinical trial 0 https://immunocine.com/timeline/

CEO needs to give some insight on trials to get price going. He won't let the price go up tellls people warrants floor 1 dollar cheaper than the current price and him and the board don't care what happens to the price because they own few shares. He needs to partner with a big company or sell to them.  I have 1/6 of shares 100k over all of these known holders not sure why my name not disclosed but maybe because individual.

Get ready dudes!!!TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

Forest green with clear blue skies dudes!!!
https://www.biospace.com/business/jpm25-day-two-roche-amgen-merck-lilly-and-biogen

Let’s go TTX CRISPR🚀🚀🚀🚀🚀

Soak it up Brothers🚀🚀🚀Shorts Hyper Thin on Ammo! Only 3000 Short Shares remain Now...the squeeze is imminent 🚀🚀🚀🚀🚀

Y’All ready
https://www.geneonline.com/what-is-tech-giant-nvidia-doing-now-latest-collabs-building-the-healthcare-puzzle-one-byte-at-a-time/

It’s coming brothers 🚀🚀🚀An SRC is a group of clinicians and other experts that oversee patient safety during a clinical trial. The SRC determines whether and how a study should proceed, including dose escalation and de-escalation decisions in accordance with the study design. Enrollment into this study continues based on the SRC's cumulative safety data review. We are very pleased with the commitment from our clinical sites which may enable quick completion of the third cohort," commented Sue Duggan, TransCode's Senior Vice President of Operations.

Nobel Micro RNA Breakthrough brothers l, it’s coming….

The upcoming dilution session being voted on in the coming weeks will also dampen any momentum the stock might make unless the company releases news of the drugs effectiveness against the tumors. That and only that will help propel te stock PPS in my opinion.

Although I am happy to see that they are progressing to Cohort 3 as expected, what will really drive the PPS higher would be need to the effect showing that the treatment has stopped progression and reduction in tumor sizes. That's what would send the PPS parabolic in my opinion. Only those who are undergoing the treatment know for sure if working and also how their body is reacting compared to receiving chemotherapy and radiation treatment.

The Holy grail of cancer research brother!! Making history right there🚀🚀🚀🚀🚀

New hope for terminally ill cancer patients

Hail Breakthrough 🚀🚀🚀🚀🚀🚀

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial
January 14 2025 - 8:00AM
PR Newswire (US)

Share On Facebook
Follows Safety Review Committee (SRC) approval based on safety data from patients in Cohorts 1 and 2

No significant safety or dose limiting toxicities reported in Cohorts 1 and 2
PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results
BOSTON, Jan. 14, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the first patient in Cohort 3 of its Phase 1 clinical trial has been dosed with TTX-MC138, its lead candidate. The Safety Review Committee monitoring the clinical trial unanimously approved opening of the third cohort based on its favorable review of Cohort 1 and 2 safety and pharmacokinetic (PK) data. Additional Cohort 3 patients have been scheduled. The dose administered to patients in the third cohort is approximately double the dose administered to those in the second cohort.

Logo (PRNewsfoto/TransCode Therapeutics, Inc.)

Several patients in the first and second cohort remain on study for continued treatment, receiving additional doses of TTX-MC138. No significant safety or dose limiting toxicities have been reported. Analyses of PK data and pharmacodynamic (PD) activity from Cohorts 1 and 2 is ongoing. To date, the analyses suggest that TTX-MC138 demonstrates a PK/PD profile consistent with preclinical results and results from TransCode's previous Phase 0 clinical trial. Specifically, results from Cohort 1 confirmed the Phase 0 observation that TTX-MC138 shows evidence of pharmacodynamic activity in the presence of high baseline expression of miR-10b, reaching a 66% inhibition at 24 hours after infusion, similar to that seen in the Phase 0 trial. Additionally, TTX-MC138 activity increased with the escalated dose administered in Cohort 2 and was consistent at subsequent administrations of TTX-MC138, suggesting a favorable pharmacokinetic profile.

"An SRC is a group of clinicians and other experts that oversee patient safety during a clinical trial. The SRC determines whether and how a study should proceed, including dose escalation and de-escalation decisions in accordance with the study design. Enrollment into this study continues based on the SRC's cumulative safety data review. We are very pleased with the commitment from our clinical sites which may enable quick completion of the third cohort," commented Sue Duggan, TransCode's Senior Vice President of Operations.

About TTX-MC138

TTX-MC138 is a first-in-class therapeutic candidate designed to inhibit microRNA-10b, or miR-10b, a microRNA widely believed to be critical to the emergence and progression of many metastatic cancers. TransCode's 2023 Phase 0 clinical trial produced evidence of delivery of a radiolabeled version of TTX-MC138 to metastatic lesions and pharmacodynamic activity, even at a microdose of the drug candidate, suggesting a broad therapeutic window for TTX-MC138.

About the Trial

TransCode's Phase 1 clinical trial is a multicenter, open-label, dose-escalation and dose-expansion study designed to generate critical data to support evaluation of the safety and tolerability of TTX-MC138 in patients with a variety of metastatic solid cancers. While not an endpoint, the trial may provide early evidence of clinical activity of TTX-MC138. The trial comprises an initial dose-escalation stage followed by a dose-expansion stage. The primary objective of the dose-escalation stage is to evaluate the safety and tolerability of escalating dose levels of TTX-MC138. In the dose-expansion stage, the safety, tolerability and anti-tumor activity of TTX-MC138 will be further evaluated in certain tumor types selected based on preliminary results from the dose-escalation phase.

Further information is available at www.clinicaltrials.gov NCT Identifier: (NCT06260774).

About TransCode Therapeutics

TransCode is a clinical-stage oncology company focused on treating metastatic disease. The company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.

Looks like they announced today as they should have that Cohort 3 is set to begin now doubling Cohorts 2 dosing levels. Good news so far with no adverse events.

Company needs to be bought

I'm all tuned in DR King!

Earthquake coming… Stay tuned…

Bingo brothers https://finance.yahoo.com/news/jp-morgan-2025-gsk-acquires-122418800.html

Live the dream in boston brothers
https://www.bostonglobe.com/2025/01/13/business/jpmorgan-conference-moderna-biogen/?p1=SectionFront_Feed_ContentQuery&p1=SectionFront_Feed_ContentQuery

Sabby a 10% owner 1/3/2025

Transcode Therapeutics, Inc.(b)Address of issuer's principal executive offices:

6 LIBERTY SQUARE, #2382, BOSTON, MASSACHUSETTS, 02109Item 2. (a)Name of person filing:

Sabby Volatility Warrant Master Fund, Ltd.
Sabby Management, LLC
Hal Mintz
(b)Address or principal business office or, if none, residence:

Sabby Volatility Warrant Master Fund, Ltd.
c/o Captiva (Cayman) Ltd
Governors Square, Bldg 4, 2nd Floor
23 Lime Tree Bay Avenue
P.O. Box 32315
Grand Cayman KY1-1209
Cayman Islands


Sabby Management, LLC
7012 Fisher Island Dr.
Miami Beach, FL 33109

Hal Mintz
c/o Sabby Management, LLC
7012 Fisher Island Dr.
Miami Beach, FL 33109(c)Citizenship:

Sabby Volatility Warrant Master Fund, Ltd. - Cayman Islands
Sabby Management, LLC - Delaware, USA
Hal Mintz - USA
(d)Title of class of securities:

Common Stock(e)CUSIP No.:

89357L402Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:(a)   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);(b)   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);(c)   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);(d)   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);(e)   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);(f)   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);(g)   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);(h)   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);(i)   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);(j)   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), 
       please specify the type of institution:(k)   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). Item 4.Ownership(a)Amount beneficially owned:

Sabby Volatility Warrant Master Fund, Ltd. - 69,555

Sabby Management, LLC - 69,555

Hal Mintz - 69,555(b)Percent of class:

Sabby Volatility Warrant Master Fund, Ltd. - 9.9%

Sabby Management, LLC - 9.9%

Hal Mintz - 9.9%   %
(c)Number of shares as to which the person has:
 (i) Sole power to vote or to direct the vote:

0
 (ii) Shared power to vote or to direct the vote:

69,555

 (iii) Sole power to dispose or to direct the disposition of:

0
 (iv) Shared power to dispose or to direct the disposition of:

69,555

Item 5.Ownership of 5 Percent or Less of a Class. Item 6.Ownership of more than 5 Percent on Behalf of Another Person. Not ApplicableItem 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. Not ApplicableItem 8.Identification and Classification of Members of the Group. Not ApplicableItem 9.Notice of Dissolution of Group. Not Applicable

Item 10.Certifications: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.



    SIGNATURE  After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 SABBY MANAGEMENT, LLC Signature:/S/ ROBERT GRUNDSTEINName/Title:COODate:01/03/2025 SABBY VOLATILITY WARRANT MASTER FUND LTD Signature:/S/ ROBERT GRUNDSTEINName/Title:COO OF INVESTMENT MANAGERDate:01/03/2025 HAL MINTZ With:5Sole Voting Power

0.006Shared Voting Power

69,555.007Sole Dispositive Power

0.008Shared Dispositive Power

69,555.009

Signature:/S/ HAL MINTZName/Title:HAL MINTZ

You bought too many shares you pushed it up to $3 lol
was trying to slowly load at $2.60s was hitting the bid earlier .....lol

Oh wow, you got a great price. I'm in now @ $2.86😅

History will repeat itself here. It will be a slam dunk! Patients pay dividends!🤩

$2.69 - 17-% Yes been waiting for the bottom bottom adding free shares via flip profits. Those profits been dwindling via Noble Prize claims lol..

Very interesting here🤭

Looks good and beat down picked up $2.60s and $2.70s Volume coming in on dilution 

We should be hearing something next week since last trial news was back on December 18 and I believe dose escalation was supposed to be looked at every 28 days.

The Market Makers swallowing up someone's Stop Losses.......

GoIng down the tubes quicker than shit!!!

Great job Fitzgerald!!!!

please stop replying to me with pump posts. Or anything to do with rapist Trump. thanks

Healthcare dealmakers eye M&A resurgence in second Trump term

Private equity firms expected to spur deals
Investors await Trump's healthcare policies
Cancer treatments, weight-loss drugs among hot areas

https://www.reuters.com/markets/deals/healthcare-dealmakers-eye-ma-resurgence-second-trump-term-2025-01-13/

Blue Sky Breakthrough on all radar screens
https://www.jpmorgan.com/about-us/events-conferences/health-care-conference

https://x.com/RNAoncology/status/1868660336813039904?lang=ar&mx=2

Orphan drug status is the bomb 💣

watching this as well. I do see NAS issue resolved for now by Jan 7 PR. These bio plays are always lottery. Orphan drug status is interesting.

Can RNAZ make history??
This premier conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.
https://www.jpmorgan.com/about-us/events-conferences/health-care-conference

Load the boat

Mergers and acquisitions JP Morgan Meeting next week https://x.com/RNAoncology/status/1868660336813039904?lang=ar&mx=2

What would happen with FDA Green light fast track compassionate use for the terminally ill cancer patients

Are you sure it’s a scam brother

Was this shorted. I bet it was.It looks like it may hjave been quick flips. But the PPS tanked due to many opther reasons. Including dilution and three R/S!

This scam is done

2.4Million market cap with 696K outstanding shares shorts sabotaged the cure to cancer brothers

FDA Fast track in the picture for compassionate use for the terminally ill cancer patients
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

Approval given after Safety Review Committee (SRC) review of safety data from the three patients comprising Cohort 2

No significant safety or dose limiting toxicities reported in Cohort 2
New patients currently being evaluated for eligibility in Cohort 3
PK and PD data from Cohort 1 patients consistent with preclinical and Phase 0 trial results
BOSTON, Dec. 18, 2024 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the Safety Review Committee (SRC) monitoring its Phase 1 clinical trial has unanimously approved opening of the third cohort of patients based on its favorable review of Cohort 2 safety data. The therapeutic candidate being evaluated, TTX-MC138, is TransCode's lead candidate designed to inhibit microRNA-10b, or miR-10b, a microRNA critical to the emergence and progression of many metastatic cancers. The dose administered to the third cohort will be approximately double the dose administered to the second cohort.

Several patients in the first and second cohort remain on study for continued treatment. No significant safety or dose limiting toxicities have been reported. Analysis of Cohort 1 data for pharmacokinetic (PK) and pharmacodynamic (PD) activity is ongoing and to date suggests that TTX-MC138 demonstrates a PK/PD profile consistent with preclinical results and results from the previous Phase 0 clinical trial. Specifically, results from Cohort 1 confirmed the Phase 0 observation that TTX-MC138 shows evidence of pharmacodynamic activity in the presence of high baseline expression of miR-10b, reaching a 66% inhibition at 24 hours after infusion. Additionally, the concentration of TTX-MC138 in blood plasma as a function of dose in humans was found to be higher than achieved in nonclinical studies, suggesting a favorable pharmacokinetic profile.

"An SRC is a group of clinicians and experts that oversee patient safety during the conduct of a clinical trial. The SRC determines whether and how a study should proceed, including dose escalation and de-escalation decisions in accordance with the study design. The recommendations of the SRC are used to decide whether a clinical trial should be continued as designed, changed, or terminated," commented Sue Duggan, TransCode's Senior Vice President of Operations. Duggan added, "Enrollment into the study continues based on the cumulative safety data review. Eligible patients may now be screened and scheduled in Cohort 3 for treatment with the next dose level of TTX-MC138 while preliminary data analysis continues."

There are many red flags to be wary of. As I mentioned, the huge PPS drop, Nasdaq issues, R/S, dilution and financial issues.As I stated they have a long way to go.


Potential Near-term Milestones
We have enrolled patients in our second cohort in our Phase I/II clinical trial and are awaiting the Safety Review Committee’s assessment to determine if we may begin dosing patients in the third cohort. Our outsourced drug manufacturing partner completed the manufacture of a GMP drug product batch for the ongoing Phase I clinical trial.
Subject to available capital, we plan to complete the stage 1a portion of our Phase I/II clinical trial upon meeting the required adaptive study design approved by the FDA, anticipated to be not later than the second quarter of 2026.
Complete the final clinical trial report for our Phase 0 clinical trial.
We have ongoing discussions with strategic partners involving a variety of our therapeutic candidates and hope to complete a partnering agreement with respect to one or more therapeutic candidates as soon as practical. We currently have no firm commitments from any strategic partners and there is no assurance that any partnering transactions will be effected.
If capital is available, we may advance development of one or more of our preclinical assets, including manufacturing activities to support IND enabling studies. If commenced, these activities would involve approximately two years as the drug candidate(s) would represent new molecular entities.
We previously obtained FDA Orphan Drug Designation and may file for European Orphan Drug Designation for TTX-MC138 in pancreatic cancer.

https://www.otcmarkets.com/filing/html?id=18031270&guid=TP0-kaRr5A2pJth

With all this exciting developments in human clinical trials with the FDA Investors believe RNAZ is a full blown scam runned by the nobel micro RNA scientific community. With 2Milion market cap 696k outstanding shares it makes it look like an empty shell company, Hell is so undervalued